Retinal side-effects of sildenafil

Lancet

Volumn 353, Issue 9150, 1999, Pages 375-

  Vobig, Michael A ^a   Klotz, Theo ^a   Staak, Michael ^a   Bartz Schmidt, Karl Ulrich ^a   Engelmann, Udo ^a   Walter, Peter ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

ARTICLE; CLINICAL TRIAL; COLOR VISION; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; HUMAN; HUMAN EXPERIMENT; IMPOTENCE; INTRAOCULAR PRESSURE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINA DISEASE; VISUAL ACUITY; VISUAL FIELD;

EID: 0033616487     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)05473-7     Document Type: Article

References (5)

1. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-404.
2. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of Sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159: 2164-71.
3. Terrett NK, Bell AS, Brown D, Ellis P. Sildenafil (Viagra™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 1996; 6: 1819-24.
4. Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-48.
5. Zrenner E. Tests of retinal function in drug toxicity. In: Hockwin O, Green K, Rubin LF, eds. Manual of Oculotoxicity Testing of Drugs. Stuttgart; Jena; New York: G Fisher; 1992: 331-61.